Azenta reports fiscal 2026 results and expects $648-$660 million revenue in 2027

Azenta, Inc. reported its financial results for the fourth quarter and fiscal year ended September 30, 2026, according to PR Newswire.

The company completed the sale of B Medical Systems on July 1, 2026, with full repayment of a $35 million vendor loan received by September 3, 2026. The historical results of B Medical Systems are reflected in the total diluted EPS as discontinued operations.

Interim President and CEO Dr. Martin Madaus stated that fiscal 2026 ended with improving momentum and stronger performance in the second half of the year, driven by strong market positions and efforts to improve commercial execution and operating efficiency.

Azenta took actions to streamline its cost structure and is focused on turning its Multiomics segment into a growth engine. For fiscal 2027, the company aims for consistent execution, accelerating performance, organic growth, expanding profitability, and cash generation.

The company expects total reported revenue from continuing operations to be between approximately $648 million and $660 million for the fiscal year ending September 30, 2027. Azenta does not provide GAAP forward-looking guidance due to difficulty in forecasting adjusting items.